Patents by Inventor Frank Pieper
Frank Pieper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9962431Abstract: A pharmaceutical composition of recombinant human fibrinogen having a half-life of less than 12 hours and a pharmaceutically acceptable carrier or diluent. The pharmaceutical composition may also contain factor VIIa, factor VIII, von Willebrand's factor, or Desmopressin. The pharmaceutical composition may also contain divalent metal cations. The recombinant human fibrinogen may contain sialic acid.Type: GrantFiled: November 5, 2015Date of Patent: May 8, 2018Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
-
Publication number: 20160106815Abstract: The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.Type: ApplicationFiled: November 5, 2015Publication date: April 21, 2016Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
-
Patent number: 9212215Abstract: A fibrinogen with reduced half-life and low sialic acid content as a result of recombinant expression or enzymatic and chemical removal. The fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.Type: GrantFiled: February 20, 2013Date of Patent: December 15, 2015Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
-
Patent number: 9211318Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: GrantFiled: February 25, 2013Date of Patent: December 15, 2015Assignee: PHARMING INTELLECTUAL PROPERTY B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Patent number: 8557773Abstract: The invention provides low-half life fibrinogen with reduced sialyation as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.Type: GrantFiled: April 29, 2009Date of Patent: October 15, 2013Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
-
Publication number: 20130267466Abstract: The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.Type: ApplicationFiled: February 20, 2013Publication date: October 10, 2013Inventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
-
Publication number: 20130244941Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: ApplicationFiled: February 25, 2013Publication date: September 19, 2013Applicant: PHARMING INTELLECTUAL PROPERTY B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Patent number: 8415288Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: GrantFiled: October 11, 2011Date of Patent: April 9, 2013Assignee: Pharming Intellectual Property B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Publication number: 20120088728Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: ApplicationFiled: October 11, 2011Publication date: April 12, 2012Applicant: PHARMING INTELLECTUAL PROPERTY B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Patent number: 8071532Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: GrantFiled: December 19, 2006Date of Patent: December 6, 2011Assignee: Pharming Intellectual Property B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Publication number: 20110263503Abstract: The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.Type: ApplicationFiled: April 29, 2009Publication date: October 27, 2011Applicant: Pharming Intellectual Property B.V.Inventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
-
Publication number: 20100305039Abstract: The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided.Type: ApplicationFiled: November 10, 2008Publication date: December 2, 2010Applicants: Pharming Intellectual Property B.V., Cohesion Technologies, Inc.Inventors: Costas N. Karatzas, Frank Pieper, Ineke De Wit, Richard Berg, Gerard Platenburg, Paul David Toman
-
Publication number: 20080305993Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: ApplicationFiled: December 19, 2006Publication date: December 11, 2008Applicant: Pharming Intellectual Property B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Publication number: 20070011754Abstract: The invention provides transgenic nonhuman mammals producing phosphorylated lysosomal proteins in their milk, and methods of generating the same. Phosphorylation occurs at the 6? position of a mannose side chain residue. Also provided are methods of purifying lysosomal proteins from milk, and incorporating the proteins into pharmaceutical compositions for use in enzyme replacement therapy.Type: ApplicationFiled: June 2, 2006Publication date: January 11, 2007Inventors: Arnold Reuser, Ans T. Ploeg, Frank Pieper, Martin Verbeet
-
Publication number: 20060142220Abstract: The present invention relates to a method for changing the half-life of a glycosylated compound by the modification of its O-linked carbohydrates. This modification is preferably carried out enzymatically and aimed at extending the half-life of the compound. Both in vivo and in vitro modification protocols may be used.Type: ApplicationFiled: October 17, 2003Publication date: June 29, 2006Inventors: Patrick Berkel, Maurice Mannesse, Frank Pieper
-
Publication number: 20050223416Abstract: The invention provides transgenic nonhuman mammals expressing C1 inhibitor in their milk. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring immunosuppression.Type: ApplicationFiled: March 22, 2005Publication date: October 6, 2005Applicant: Pharming Intellectual Property B.V.Inventors: Johannes Nuijens, Henricus Van Veen, Frank Pieper, Joris Heus
-
Publication number: 20050198698Abstract: Transgenes for producing recombinant polypeptides transgenic bovine species. A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal sequence which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptide. Also included are methods for producing transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk.Type: ApplicationFiled: November 12, 2004Publication date: September 8, 2005Applicant: Pharming B.V., a Netherlands corporationInventors: Herman DeBoer, Rein Strijker, Herbert Heyneker, Gerard Plantenburg, Sang Lee, Frank Pieper, Paul Krimpenfort
-
Publication number: 20050172342Abstract: The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided.Type: ApplicationFiled: December 18, 2003Publication date: August 4, 2005Applicants: Pharming B.V., Cohesion Technologies, Inc.Inventors: Costas Karatzas, Frank Pieper, Ineke De Wit, Richard Berg, Gerard Platenburg, Paul Toman
-
Patent number: 6713662Abstract: The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided.Type: GrantFiled: June 7, 1995Date of Patent: March 30, 2004Assignees: Pharming Intellectual Property B.V., Cohesion TechnologiesInventors: Costas N. Karatzas, Frank Pieper, Ineke De Wit, Richard Berg, Gerard Platenburg, Paul David Toman
-
Publication number: 20030192068Abstract: Transgenes for producing recombinant polypeptides transgenic bovine species. A transgene for producing recombinant polypeptides in the milk of transgenic bovine species comprises at least one expression regulation sequence, a secretory DNA sequence encoding a secretory signal sequence which is functional in mammary secretory cells of the bovine species and a recombinant DNA sequence encoding the recombinant polypeptide. Also included are methods for producing transgenic bovine species. The method includes introducing the above transgene into an embryonal target cell of a bovine species, transplanting the transgenic embryonic target cell formed thereby into a recipient bovine parent and identifying at least one female offspring which is capable of producing the recombinant polypeptide in its milk.Type: ApplicationFiled: June 11, 2002Publication date: October 9, 2003Applicant: Pharming B.V.Inventors: Herman A. DeBoer, Rein Strijker, Herbert L. Heynecker, Gerard Platenburg, Sang Ha Lee, Frank Pieper, Paul J.A. Krimpenfort